MIM
NPCE icon

MetLife Investment Management’s Neuropace NPCE Stock Holding History

MetLife Investment Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Hold
15,288
– – ﹤0.01% 2225
2025
Q4 		$236K Hold
15,288
– – ﹤0.01% 2192
2025
Q3 		$158K Hold
15,288
– – ﹤0.01% 2445
2025
Q2 		$170K Buy
15,288
+6,083
+66% +$76.1K ﹤0.01% 2272
2025
Q1 		$113K Hold
9,205
– – ﹤0.01% 2471
2024
Q4 		$103K Buy
+9,205
New +$80K ﹤0.01% 2610

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

MetLife Investment Management's NPCE Position: Q1 2026 in Review

MetLife Investment Management held its Neuropace (NPCE) position steady in Q1 2026 at 15,288 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #2225.

MetLife Investment Management first reported a position in NPCE in Q4 2024 and has held it in 6 quarters since. The position peaked at $236K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • MetLife Investment Management held 15,288 shares of Neuropace worth $201K as of Q1 2026.
  • MetLife Investment Management left its Neuropace share count unchanged in Q1 2026.
  • Neuropace made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2225 holding.
  • MetLife Investment Management first reported a position in Neuropace in Q4 2024 and has held it in 6 quarters since.
  • MetLife Investment Management's Neuropace position peaked at $236K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.